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Outcomes of patients on dual-boosted PI regimens: experience of
the Swiss HIV cohort study
Abstract
Dual-boosted protease inhibitors (DBPI) are an option for salvage therapy for HIV-1 resistant patients.
Patients receiving a DBPI in the Swiss HIV Cohort Study between January1996 and March 2007 were
studied. Outcomes of interest were viral suppression at 24 weeks. 295 patients (72.5%) were on DBPI
for over 6 months. The median duration was 2.2 years. Of 287 patients who had HIV-RNA
>400 copies/ml at the start of the regimen, 184 (64.1%) were ever suppressed while on DBPI and 156
(54.4%) were suppressed within 24 weeks. The median time to suppression was 101 days (95%
confidence interval 90-125 days). The median number of past regimens was 6 (IQR, 3-8). The main
reasons for discontinuing the regimen were patient's wish (48.3%), treatment failure (22.5%), and
toxicity (15.8%). Acquisition of HIV through intravenous drug use and the use of lopinavir in
combination with saquinavir or atazanavir were associated with an increased likelihood of suppression
within 6 months. Patients on DBPI are heavily treatment experienced. Viral suppression within 6
months was achieved in more than half of the patients. There may be a place for DBPI regimens in
settings where more expensive alternates are not available.
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Abstract
Dual-boosted protease inhibitors (DBPI) are an option for salvage therapy for HIV-1 resistant patients. Patients
receiving a DBPI in the Swiss HIV Cohort Study between January1996 and March 2007 were studied. Outcomes
of interest were viral suppression at 24 weeks. 295 patients (72.5%) were on DBPI for over 6 months. The median
duration was 2.2 years. Of 287 patients who had HIV-RNA >400 copies/ml at the start of the regimen, 184
(64.1%) were ever suppressed while on DBPI and 156 (54.4%) were suppressed within 24 weeks. The median
time to suppression was 101 days (95% confidence interval 90–125 days). The median number of past regimens
was 6 (IQR, 3–8). The main reasons for discontinuing the regimen were patient’s wish (48.3%), treatment failure
(22.5%), and toxicity (15.8%). Acquisition of HIV through intravenous drug use and the use of lopinavir in
combination with saquinavir or atazanavir were associated with an increased likelihood of suppression within 6
months. Patients on DBPI are heavily treatment experienced. Viral suppression within 6 months was achieved in
more than half of the patients. There may be a place for DBPI regimens in settings where more expensive
alternates are not available.
Introduction
Antiretroviral therapy has undergone many chan-ges over the course of the last 20 years and has resulted in
decreased morbidity and mortality among HIV-infected pa-
tients.1 However, in clinical practice, factors such as poor ad-
herence, limited potency of prior regimens, and drug toxicity
have led to an increased prevalence of multiple resistance mu-
tations in both reverse transcriptase and protease sequences.2
Treatment options after the accumulation of several pro-
tease inhibitor (PI) mutations are limited and usually require
the use of newer agents such as integrase inhibitors (ralte-
gravir [RAL], salvage PIs (tipranavir [TPV], and darunavir
[DRV]), new generation non-nucleoside reverse transcrip-
tase inhibitors (NNRTIs) such as etravirine (ETV) or entry
inhibitors (fusion [T-20] or CCR5 inhibitors (maraviroc
[MVC]).3 Before the availability of these new drugs, many
clinicians used different salvage strategies in the treatment of
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multidrug-resistant HIV. Some of these regimens included
two PI in addition to low-dose ritonavir (RTV, dual-boosting).
RTV, a potent inhibitor of the cytochrome P450 enzymatic
system, is extensively used as an adjunct to PI therapy (as a
booster).4 The increase in levels of co-administered PI due to
this drug–drug interaction has allowed for simpler and less
toxic regimens to be adopted for the treatment of HIV.5 In
addition, the enhanced pharmacokinetic profile (in particular,
Cmin and Area Under the Curve, AUC) of the boosted drug
enables better viral suppression6 and a higher threshold for the
development of resistance than if used without RTV.7–9 De-
spite early studies showingmarginally increased side-effects,5
boosted PI therapy has become part of the standard of care for
the treatment of naı¨ve and experienced patients,10,11 particu-
larly because of their high genetic barrier to resistance.12–14
Similarly, the use of dual-boosted regimens has gained fa-
vor due to some studies reporting on synergistic and additive
effects of PI combinations with little additive toxicity.15–21 In
addition, the concept of maintaining high plasma levels of two
drugs, with distinct resistance profiles, will enable each drug
to retain activity against the susceptible viral quasi-species in
the presence of multiple PI resistance mutations is appealing.
This approach has become more popular in recent years
with the approval of atazanavir (ATV), which has less meta-
bolic toxicity22 and therefore is deemed safer when used in
addition to conventional PIs. Several pharmacokinetic studies
have also shown that double-boosted protease inhibitors
(DBPI) have a relatively safe profile, especially ATV co-ad-
ministered with saquinavir (SQV) or lopinavir/ritonavir
(LPV-r).16,19,20 23 Few clinical observational studies showed
that ATV combined with LPV-r23 was well-tolerated and ef-
ficient in patients with extensive treatment experience.
Although former recommendations issued by the interna-
tional AIDS society–USA panel stated that "there are no
convincing data to support the use of a DBPI and these regi-
mens should be avoided",24 DBPI regimens were used widely
in clinical practice due to lacking alternatives in salvage
therapy. Despite this assertion, there are very few published
studies regarding outcomes in large cohorts, and a recent
small randomized controlled trial favored DBPI in an as-
treated analysis.25 There will likely never be a large trial to
determine the relative efficacy and toxicity of the multitudes
of combinations of DBPI available which could refute or
confirm this hypothesis. Nevertheless, one needs to consider
that in many parts of the world, widespread roll-out of anti-
retrovirals with low frequency of viral load monitoring is
leading to the emergence of severe drug resistance. In addi-
tion, potent anti-retrovirals such as integrase inhibitors and
new generationNNRTIs are unfortunately not yet available in
most resource-constrained settings.26–28 This means that DBPI
regimens may be the only salvage regimens available in pa-
tients who have multi-class failure in some countries. We
therefore aimed to characterize the patients who have re-
ceived DBPI regimens within the Swiss HIV Cohort Study
(SHCS) and to identify independent factors predicting viral
suppression at 6 months on a DBPI regimen.
Methods
Study design
This is a retrospective analysis of data recorded in the
context of a prospective observational cohort of all patients
enrolled in the SHCS since its inception (1987) and who re-
ceived a treatment regimen containing RTV and two other PIs
between January 1996 and March 30, 2007.
The SHCS is a longitudinal cohort that collects information
on a bi-annual basis on more than 14,000 patients from seven
participating centers in Switzerland. The detailed structure of
the SHCS has been described elsewhere.29,30 We collected
data on demographical information and results of laboratory
tests at cohort visits (CD4 cell count, HIV-1 RNA, and lipid
profiles), treatment regimens, and reasons for switching
regimens.
Definitions
 DBPI was defined as the use of RTV in combination with
two other PIs. Patients who received nelfinavir (NFV) in
this combination were also included in the study, despite
evidence that NFV is not significantly boosted by RTV.
Patients who received newer PIs in salvage therapy, no-
tably DRV and TPV, were excluded from the study. We
also did not consider full-dose RTV in combination with
SQV as a DBPI equivalent and therefore excluded pa-
tients on this particular combination from the study.
 HIV RNA suppression was defined as a viral load of
<400 copies/ml. We chose this cutoff because it most
accurately identifies all episodes of suppression across
the time-span chosen within the cohort. Cutoffs for
suppression were changed during the 10 years of ob-
servation that we chose (from <400 copies/ml to
<20 copies/ml) with the final cutoff recorded in the
cohort being dependent on the laboratory method used
at a given time. Additionally, patients who were con-
sidered suppressed were assigned an RNA value of zero
in the database and therefore the real value for these
patients cannot be determined retrospectively.
Laboratory values
CD4 count and HIV RNA viral load at cohort entry were
defined as the first value recorded within the cohort. These
values do not necessarily represent the laboratory values
present at the time of HIV-1 diagnosis for each patient.
CD4 count and HIV RNA viral load at the time of DBPI
start were calculated within a time range so as to most accu-
rately reflect the values available to the clinician. For CD4
counts, we considered all values within 30 days of the event of
interest (cohort start, DBPI start, DBPI stop, cohort exit) and
chose the value closest to the date of the event within those 30
days. Since HIV RNA is more often used for clinical decision
making, we took into consideration values that were closest to
the sixth month after DBPI start, up to 30 days before but no
more than 10 days after. The value of HIV-RNA up to 10 days
after the cohort visit would be an accurate reflection of the
value available to the clinician at the time clinical decision-
making occurred.
For HDL and cholesterol values, we chose the value that
was closest to the event of interest, either before or after the
event but within 30 days.
Treatment interruptions and changes
Any instance where the patient recorded as not being on
therapy either before or after the regimen of interest was
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considered as a treatment interruption, regardless of the du-
ration or reason for the treatment interruption (intercurrent
illness, physician’s decision or patient’s decision for example).
The number of regimen changes was calculated based on
the change of any drug within the regimen, and was not
limited to the PI class.
The duration of zidovudine (AZT) monotherapy and nu-
cleoside reverse transcriptase inhibitors (NRTI) bi-therapy
alone is based on the cumulative time the patient received
these regimens, irrespective of treatment interruptions within
this time. However, patients had to have gone back to the
original regimen in order for the time to be included (i.e.,
patients who switched from AZT to bi-therapy and then back
to AZT were not considered to be on AZT monotherapy for
that entire time period). NNRTI experience was defined as the
receipt of a regimen containing efavirenz (EFV), nevirapine
(NVP), or delavirdine (DLV) before the onset of the DBPI
regimen, regardless of the concomitant drugs in the regimen.
NNRTI co-administrationwas defined as the receipt of EFV
or NVP in conjunction with the DBPI regimen.
Outcomes
Outcomes of interest were characteristics of the patients
who received DBPI, particularly for those who received the
regimen for less than 6 months versus those who continued
the regimen for longer periods, time to viral suppression for
all patients included in the study, and the proportion of pa-
tients who achieved a viral suppression in less than 180 days
after the start of the DBPI regimen. In addition, factors asso-
ciated with duration of DBPI therapy were investigated.
Statistical analysis
Simple descriptive statistics were used to describe the
study population. To compare the group that achieved sup-
pression to the one that did not, the Pearson chi-square test
was used for categorical data, as well as Fisher’s exact test
when required, and Student t-test, as well as Wilcoxon rank
sum test for continuous data. The logistic regression model
was used for dichotomous outcomes. Adjustment was per-
formed for at most one or two factors at a time to assess
conditional associations. No specific model selection was
performed and results are mainly descriptive.
Results
Baseline characteristics
We identified 407 patients who received DBPI during the
study period and 295 patients who received DBPI for at least 6
months. Patients who received more than 6 months of treat-
ment and those who stopped early did not differ significantly
in age, gender distribution, mode of HIV acquisition, regi-
mens used, or cohort outcome. However, patients who re-
ceived DBPI for longer than 6 months tended to be different
from those who stopped the treatment earlier regarding HIV
RNA at DBPI start (4.6 log vs. 3.6 log, p< 0.01), mean CD4
counts at enrollment (260 vs. 356.5, p¼ 0.02 [not importantly
significant]), and a tendency for lower CD4 count at DBPI
start (187 vs. 225, p¼ 0.05, idem). Moreover, more patients
were experiencing virological failure at the time of DBPI start
in the group who pursued treatment for more than 6 months
(73.6% vs. 61.6%, p¼ 0.02). The two groups also differed with
respect to treatment experience before DBPI start. Patients
who stopped early (<6 months) had been on antiretroviral
treatment for a median of 5.9 years (interquartile range [IQR]
3.1–8.8) compared to 7.3 years (IQR 4.9–9.2) in patients who
continued DBPI for longer ( p< 0.01).
Characterization of DBPI group
We will then describe the 295 patients who underwent
DBPI treatment for at least 6 months. They had a median age
of 43 years (IQR: 38–49) and were mostly male (76.9%,
n¼ 227). The most common risk factor for HIV acquisition
was men-having-sex-with-men (MSM) (43.4%, n¼ 128), fol-
lowed by heterosexual contact (29.8%, n¼ 88), and intrave-
nous drug use (23.1%, n¼ 68). Eleven patients had either an
unknown risk factor or acquired HIV through blood trans-
fusions. A total of 248 patients (84.1%) were still active in the
cohort at the time of the last follow-up visit. Thirty-three pa-
tients died (11.2%) since they were first enrolled between
January 1996 and March 30, 2007 and only 14 (4.7%) had
either withdrawn from the SHCS or were lost to follow-up on
March 30, 2007. The cause of death was related to HIV in 17
patients (5.8%). Table 1 summarizes the characteristics of the
patients as well as the treatment experience before starting
therapy.
Treatment interruptions
To better characterize the treatment experience of our co-
hort, we analyzed the number of treatment interruptions that
had occurred before the start of DBPI as well as the number of
regimen changes before and after the DBPI regimen. Ninety
patients (30.5%) had never interrupted their treatment before
starting the DBPI regimen, 102 patients (34.6%) had inter-
rupted a regimen once, while 94 (31.9%) had done so two to
five times. There were 9 patients (3.1%) who had between six
and ten treatment interruptions prior to starting DBPI. For the
regimen changes, 135 patients (45.8%) experienced between
one and five regimen changes prior to starting DBPI. 116
(39%) had 6–10 changes and 33 (11.2%) had 11–15 changes.
There were 9 patients (3.1%) who had more than 15 different
regimens from the time of enrollment. The median number of
changes after the DBPI regimen was 2 (IQR:1–4) (Table 1).
DBPI regimens used and duration on therapy
LPV-r was the most common PI used in our DBPI cohort. A
total of 240 (81.4%) patients were receiving LPV-r in combi-
nation with one other PI. The most common combination was
LPV-r/amprenavir (LPV-r/APV) used in 110 (37.3%) pa-
tients, followed by LPV-r/SQV in 82 (27.8%) patients. SQV-r/
ATV was given to 36 (12.2%) patients. Eighty-eight (29.8%)
patients also received concomitant NNRTI and 19 (6.4%)were
receiving fusion inhibitors. The number of drugs in the regi-
men ranged from three to more than six, with 129 patients
receiving four drugs (43.7%) and 15 (5.1%) receiving more
than six drugs concomitantly. We subdivided the cohort ac-
cording to the year DBPI therapy was begun and found that
227 (76.9%) patients had started DBPI after the year 2000 and
only 68 patients had been started on a DBPI regimen before
the year 2000 (Table 2).
The DBPI regimen was stopped in 120 (40.7%) patients
before the end of the follow-up period. The most common
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reason for stopping was provider decision or patient prefer-
ence (48.3%, n¼ 58). Treatment failure accounted for the
withdrawal of the regimen in 27 (22.5%) and toxicity in 19
(15.8%) patients. In these 19 patients, dyslipidemia, elevated
cardiovascular risk, and abnormal fat distribution prompted
the regimen change in 8 (42.1%) cases, and GI symptoms,
including elevated liver enzymes, were present in 7 (36.9%).
The remaining 4 patients discontinued due to endocrine,
nervous system, or other unspecified toxicities.
Of note when compared to the group of patients who had
early switches and never received DBPI for longer than 6
months, toxicity accounted for the treatment withdrawal in 29
(35.4%) of the 112 patients. This difference was statistically
significant ( p¼ 0.02). There were no significant differences in
the group who stopped early compared to the group who
received treatment for over 6 months with respect to patient
or provider preference as a reason for stopping the regimen or
the occurrence of virological failure.
Virological response to DBPI treatment
Virological suppression defined as a HIV RNA <400 cop-
opies/ml was observed in 184 (64.1%) of the 287 patients who
had a virological failure at the start of the DBPI regimen and
156 (54.4%) achieved suppression within 24 weeks of starting
the regimen. Of all 287 patients, 170 (79.1%)who are still in the
cohort by the end of May 2009 were suppressed at their last
follow-up appointment and 148 (68.8%) had an HIV-RNA of
Table 1. Baseline Characteristics and Treatment Experience of Patients on Dual-Boosted Protease
Inhibitors in the Swiss HIV Cohort Study, January 1996–March 2007
Variable (unit)
All patients
N¼ 407 (%), [IQR]
DBPI> 6 months
N¼ 295 (%), [IQR]
Time from ART start to DBPI start (years) 7.0 (4.4–9.1) 7.3 (4.9–9.2)
Median time on DBPI
Days 520 (159–1126) 799 (421–1443)
Years 1.4 (0.4–3.1) 2.2 (1.2–3.9)
CD4 Nadir (median, cells/mm3) 66 (20–151) 61 (16–136)
D4 at start of cohort (median, cells/mm3) 286 (134–470) 260 (120–445)
CD4 at last follow-up or exit (median, cells/mm3) 360 (163–533) 361 (183–539)
RNA at start of cohort (log10) 4.6 (3.5–5.2) 4.7 (3.7–5.2) n¼ 240
RNA at start of DBPI treatment (log10) 4.6 log (3.4–5.2]
Azt monotherapy exposure 198 (48.9) 153 (52)
NRTI bi-therapy 265 (65.4) 201 (68.1)
Single PI exposure before starting DBPI 332 (81.9) 251 (85.4)
NNRTI exposure before starting DBPI 250 (61.7) 181 (61.6)
RTV-SQV experience before DBPI start 179 (44) 134 (45.4)
Number of treatment interruptions
before DBPI start (median)
1 [0–2] 1 [0–2]
None 116 (28.5) 90 (30.5)
One 137 (47.1) 102 (34.6)
Two–Five 142 (48.8) 94 (31.9)
Six–Ten 12 (4.1) 9 (3.1)
Number of regimen changes before DBPI start 6 [3–9] 6 [ 3–8]
None 24 (9.4) 15 (5.1)
1–5 172 (42.3) 122 (41.4)
6–10 152 (37.3) 116 (39.0)
11–15 49 (12.0) 33 (11.2)
>16 10 (2.5) 9 (3.1)
Number of Changes after DBPI stop 2 [1-4] 2 [1–4]
DBPI Regimen
Containing LPV/r 318 (78.1) 240 (81.4)
Containing SQV 174 (42.7) 130 (44.1)
Containing RTV 104 (25.5) 58 (19.7)
Containing APV 141 (34.6) 116 (39.4)
Containing ATV 96 (23.6) 63 (21.4)
Containing IDV 41 (10.1) 17 (5.8)
Containing fos-APV 14 (3.4) 13 (4.4)
Concomitant NNRTI 111 (27.3) 88 (29.8)
Concomitant T-20 25 (6.1) 19 (6.4)
Number of drugs in regimen
2 16 (3.9) 13 (4.4)
3 101 (24.8) 84 (28.5)
4 179 (44.0) 129 (43.7)
5 84 (20.6) 54 (18.31)
6 27 (6.6) 15 (5.1)
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less than 50 copies/ml at their last follow-up. The median
time to suppression was 101 days (95% confidence interval,
95% CI: 90–125 days).
We compared the baseline characteristics of the patients
who achieved suppression in the first 24weeks and those who
did not in an ‘‘intention to treat analysis’’ (i.e., irrespective of
the treatment duration). Patients who achieved suppression
were more likely to be intravenous drug users ( p¼ 0.01), had
a lower CD4 at cohort entry ( p¼ 0.01), and a lower HIV-RNA
at the start of DBPI therapy, and were more likely to start
DBPI after the year 2000. In terms of outcomes, patients who
did not achieve suppression had a higher mortality (22.1% vs.
7.1%, p¼ 0.001), and had a lower median CD4 gain during
therapy (þ96.6 vs. þ195.2 cells/mm3, p< 0.0001). These pa-
tients also differed significantly in terms of exposure to SQV-
RTV before starting DBPI and the use of LPV-r/SQV as a
DBPI regimen (Table 2).
Toxicity
Regarding toxicity of DBPI, there was no significant dif-
ference in lipid values before and after treatment in the 120
patients who had a lipid profile available within 100 days of
starting or stopping the DBPI regimen. The mean change in
cholesterol values before and after DBPI therapy was
0.49mmol/l (95%CI:0.96 to0.02; p¼ 0.05) and themean
Table 2. Characteristics of Patients Who Achieved Suppression in Less Than 6 months and Who Received
More Than 6 Months of DBPI, and Were Failing Therapy at the Start of DBPI
Variable
RNA< 400 copies/ml
N¼ 141 (%), [IQR]
RNA> 400 copies/ml
N¼ 77 (%), [IQR] p Value
Age 43.9 [38–49] 42 [37–46] 0.11
Ethnicity (Caucasian) 120 (85.1) 71 (92.2) 0.13
Gender (male) 107 (75.9) 63 (81.2)
Riskgroup 0.01
Heterosexual 46 (32.6) 21 (27.7)
IDU 41 (29.1) 10 (12.9)
MSM 49 (34.7) 42 (54.6)
Other 5 (3.6) 4 (5.2)
Mortality 10 (7.1) 17 (22.1) 0.0013
CD4 at start of DBPI (median) 184.4 (73.5–256.5) 162.3 (21–242) 0.081
CD4 Category at start
<200 cells/ml 73 (58.9) 46 (65.7) 0.51
200–350 cells/ml 38 (30.6) 16 (22.9)
>350 cells/ml 13 (10.5) 8 (11.4)
CD4 at cohort entry (median) 295.7 (79–390) 341.5 (174–450) 0.013
VL at cohort entry (log10) 4.41 (3.9–5.1) 4.68 (4.1–5.2) 0.045
VL at start of DBPI (log10) 4.56 (3.7–5.2) 4.95 (4.7–5.4) 0.0011
Treatment year (start)
1996–1999 2 (1.4) 8 (10.4) 0.002
2000–2002 72 (51.1) 48 (62.3)
2003–2004 44 (31.2) 14 (18.2)
>2004 23 (16.3) 7 (9.1)
Year of DBPI start 0.0003
Before 2000 28 (19.9) 33 (42.9)
After 2000 113 (80.2) 44 (57.1)
RTV-SQV before DBPI start 57 (40.4) 44 (57.2) 0.02
AZT monotherapy (received) 76 (53.9) 44 (57.1) 0.64
NRTI bitherapy (received) 95 (67.4) 55 (71.4) 0.54
Regimen used
LPV-r/AMP 58 (41.2) 41 (53.2) 0.09
LPV-r/SQV 43 (30.5) 11 (14.3) 0.008
LPV-r/ATV 9 (6.4) 1 (1.3) 0.09
LPV-r/fos-AMP 6 (4.3) 3 (3.9) 0.99
SQV/RTV 18 (12.8) 15 (19.5) 0.23
SQV-r/AMP 1 (0.71) 2 (2.6) 0.28
Number of regimen changes 0.09
0 1 (0.7) 0
1–5 68 (48.2) 34 (44.2)
6–10 55 (39.0) 24 (31.2)
>11 17 (12.1) 19 (24.7)
Number of treatment interruptions 0.79
0 38 (26.9) 19 (24.7)
1–2 77 (54.6) 41 (53.2)
>2 26 (18.4) 17 (22.1)
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change in HDL was þ0.04mmol/l (95% CI 0.08 to 0.09;
p¼ 0.89).
Factors associated with virological response
A multivariable regression model was built to determine
which factors were associated with early suppression in both
patient groups. We showed that the transmission of HIV
through intravenous drug use, the start of DBPI after 1999 as
well as the use of LPV-r/SQV and LPV-r/ATV were all in-
dependently associated with an early suppression of HIV-1
RNA. However, in patients who received DBPI for longer
than 6 months, HIV-1 RNA at treatment start was strongly
associated with early suppression (OR 0.49 95% CI 0.33–0.75,
p¼ 0.0008 but treatment with LPV-r/ATV was not (Table 3).
Discussion
To our knowledge, our study is the largest published to
date describing the use of DBPI in extensively treatment-
experienced patients in detail. Several previous studies
attempting to evaluate the effectiveness of DBPI in HIV treat-
ment have been discontinued25 and a prospective trial is un-
likely to be undertaken given the newer regimens available
for therapy.
Our analysis shows that patients who received LPV-r/SQV
as part of their DBPI regimen were more likely to achieve
suppression, especially when the year of initiation of DBPI
therapy was after 2000. This may also be related to the intro-
duction of newer NRTIs such as tenofovir or abacavir, which
may have retained some activity in patients who had thymi-
dine analog mutations from exposure to single or dual NRTI
regimens in the past. Of the patients who continued to receive
DBPI, the proportion who achieve virologic suppression
(64.1%) was comparable and in some instances, better than,
those described in treatment-naı¨ve studies in the earlier years
of HIV treatment.31 Our findings also suggest comparable
suppression rates than in ‘‘real-life’’ settingswith other salvage
approaches studied in randomized controlled trials such as the
use of newer PIs, NNRTIs, and integrase inhibitors with op-
timized background regimens.32–34 In addition, the concomi-
tant use of NNRTI did not influence the outcome and both
NNRTIs and enfuviritide were used by a minority of patients
(20.5% and 5.4%, respectively). In this study, 64.6% of the 218
patients who started a DBPI due to virological failure and
continued the treatment for longer than 6 months, achieved a
viral load of <400 copies/ml. All the patients were heavily
treatment experienced,with an average of six regimen changes
before starting a DBPI regimen. Patients infected through in-
travenous drug use show better virological suppression. This
may be explained by the fact that patients who are current
intravenous drug users are more often directly observed and
therefore may have better adherence than other patients in the
cohort. While toxicity was not an issue for patients who con-
tinued on DBPI for longer than 6 months, it was a significant
reason to stop early, indicating thereby that early toxicity is a
barrier to wider use of DBPI (at a mean time of 41 days, [IQR
10.5–95]). In addition, the patients who stayed on DBPI for
longer than 6 months had a lower CD4 count, a higher viral
load andweremore treatment-experienced at the start of DBPI
compared to those who discontinued the treatment earlier.
This may represent a treatment bias towards maintenance of
DBPI regimen in patients with a more advanced disease and
higher risk for progression to AIDS.
Several small series have been published and suggested that
DBPI-based salvage regimensmay be beneficial to patients and
were responsible of few toxicity.35–38 In contrast, Petersen et al.
published results from a retrospective cohort study comparing
the efficacy of DBPI versus boosted single PI therapy in 183 and
805 patients, respectively, and concluded that there was no
statistically significant benefit to use DBPI for salvage therapy.
However, the findings did suggest that there may be a mod-
erate size benefit if the cohort had been larger.39 The authors
also point out the limitations of using a retrospective analysis of
data compared to the gold standard of a randomized double-
blind clinical trial. Similarly, Loutfy et al. found that the addi-
tion of APV to a salvage regimen containing LPV/r was not
associated with a faster time to achieve virological suppression
nor with a difference in virological rebound rates.40 Another
recent clinical trial in Thailand reported on 50 treatment-
experienced children who received SQV in combination to
LPV/r and found that there was significant rise in CD4 counts
and viral suppression<400 and<50 at 48 weeks was achieved
in 78% and 64% of cases, respectively.41 An earlier study by the
same group found that the pharmacokinetic profile of this
regimen was favorable in children.42 However, APV or SQV in
combinationwith LPV/r have fallen out of favor in recent years
due to the side-effect profile on lipids as well as due to the high
pill-burden, leading to a risk of reduced adherence. In addition,
results on pharmacokinetic interactions of APV and LPV/r
have produced conflicting results. Fosamprenavir, in combi-
nation with LPV/r, has also shown to have antagonistic
pharmacokinetic profiles and LPV/r reduces fAPV levels.25
Table 3. Multiple Logistic Regression: Factors Associated with Early Suppression (<24 Weeks)
in Patients who Received DBPI Therapy and Had HIV RNA >400Copies/ml at Start of DBPI
In all patients n¼ 287
In patients who received therapy
for >6 months, n¼ 218
Variable OR (95% CI) p Value OR (95% CI) p Value
HIV-1 RNA at start – – 0.49 (0.33–0.75) 0.0008
Treatment before 2000 0.10 (0.023–0.46) 0.003 0.08 (0.01–0.44) 0.04
Intravenous drug use 2.29 (1.26–4.18) 0.007 2.32 (1.04–5.14) 0.04
Regimens used
Lopinavir-r/Atazanavir 3.95 (1.06–14.72) 0.04 – –
Lopinavir-r/Saquinavir 2.04 (1.10–3.65) 0.003 2.56 (1.16–5.62) 0.02
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The conflicting results published so far on the general use of
DBPI may also have been related to the side-effect profile and
potency of the individual PIs studied, while studies using
newer agents were more likely to report positive findings.23
More recently, a review of published studies on DBPI con-
cluded that those combinations may play a positive role in
settings where other drugs are not available.43
Our study presents several limitations due to its observa-
tional nature exposing to potential misclassification and se-
lection bias. Patients were first not randomized and were not
compared to a controlled group, leading to the risk of selection
bias as information bias. Second, adherence data has only
systematically been collected in the SHCS since 2003,44 and
thus was not available for this study. Third, genotypic drug
resistance information was not sufficiently available for the
current study because genotyping was only prospectively
usedwidely after introduction into the SHCS in the year 2000.2
However, onemay argue that at the timewhenDBPI regimens
were widely instituted, genotypic drug resistance information
was only sparsely available, exactly reflecting the situation as
it presents today in the developing countries, where drug re-
sistance testing will not be routinely available in the near fu-
ture. These countries however are exactly the ones that might
have to depend mostly on DBPI treatments for salvage in the
future. In addition, the main criticism against the use of DBPI
in clinical practice was its potential for higher toxicity, espe-
cially regarding the higher risk for cardiovascular morbidity.
Wewere able to report before and after lipid profiles in only 47
patients, and even though this did not have any significant
increase in cholesterol, a more in-depth study would be nec-
essary to confirm these results. A retrospective pharmacoki-
netic analysis performed on stored serum samples could have
yielded more information on drug levels and the exact nature
of drug interactions. However, this would not be possible in
the present study since information about timing of the last
dose is not available and the results of any pharmacokinetic
data would therefore be difficult to interpret.
In conclusion, this retrospective analysis of a large pro-
spective observational database shows that virological sup-
pression with DBPI was reached in 64% in a highly
antiretroviral drug-exposed population. These regimens seem
to be well-tolerated with less than 20% toxicity, and hyper-
lipidemia did not seem to occur at a statistically significant
level. Moreover, 73% of patients tolerated the DBPI for a
median of 2.2 years [IQR, 1.2–3.9]. Even though potentially
safer alternatives are currently marketed in the treatment-
experienced patients, DBPI salvage regimens may only be the
one available for most people in resource-poor settings. Non
clade-B viruses are well represented in the SHCS database,45
but in our overall study population, 45 (14%) of the subtyped
viruses were non-B viruses and 1 patient was infected with
HIV-2. However, there is no evidence in the literature that
non-B viruses and HIV-2 would differ in their response to
DBPI. Therefore this salvage strategy deserves further con-
sideration in resource-poor settings as resistance to first-line
regimens, and particularly to the entire class of NRTI and first
generation NNRTIs, seems to develop at a high rate due to the
absence of viral load monitoring.26–28 Therefore, just as
heavily experienced patients in the SHCS had a benefit from
DBPI regimens at time when other therapies were not avail-
able, these regimens may also represent a bridge of survival
before more expensive drugs, widespread viral load testing,
and genotypes are widely made available for patients in re-
source-limited settings who fail current treatments.
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